Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318558 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
A Phase 3 study of Ovarian Cancer and Ovarian Neoplasms, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 9
- Study locations
NCT07318558 is a Phase 3 study of Ovarian Cancer and Ovarian Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 900 participants, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (24% higher). The trial reports 9 study locations across 5 states.
The verdict
NCT07318558, a Phase 3 study of Ovarian Cancer and Ovarian Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 9
- Study locations
Study Summary
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Rescue Medications
- DRUG Sacituzumab tirumotecan
Study Locations (9)
Other
- Rambam Health Care Campus ( Site 1422) - Haifa
- Niigata Cancer Center Hospital ( Site 1608) - Niigata
- Seoul National University Hospital ( Site 2301) - Seoul
- Asan Medical Center ( Site 2305) - Seoul
- Linkou Chang Gung Memorial Hospital ( Site 2605) - Taoyuan District
Florida
- Mount Sinai Cancer Center ( Site 0029) - Miami Beach
Iwate
- Iwate Medical University Hospital ( Site 1610) - Shiwa-gun
Tokyo
- Cancer Institute Hospital of JFCR ( Site 1614) - Koto
Seoul
- Severance Hospital ( Site 2302) - Seodaemun-Gu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2026-02-16 |
| Est. Completion | 2033-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318558
The ClinicalTrials.gov registry entry for NCT07318558 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (24% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT07318558 reports 9 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, Iwate.
Frequently Asked Questions
What is clinical trial NCT07318558 about?
NCT07318558 is a clinical study titled "A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)". Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us...
What is the current status of trial NCT07318558?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2026-02-16. Estimated completion is 2033-02-25.
What conditions does trial NCT07318558 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms.
What interventions are being tested in trial NCT07318558?
The interventions under investigation include: Bevacizumab (DRUG), Rescue Medications (DRUG), Sacituzumab tirumotecan (DRUG).
Who is sponsoring clinical trial NCT07318558?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07318558 being conducted?
This trial has 9 study locations across Florida, Iwate, Tokyo, Seoul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.